RT Journal Article
SR Electronic
T1 Scintigraphic Detection of Overexpressed c-<em>erbB-2</em> Protooncogene Products by a Class-switched Murine Anti-c-<em>erbB-2</em> Protein Monoclonal Antibody
JF Cancer Research
JO Cancer Res
FD American Association for Cancer Research
SP 990
OP 994
VO 51
IS 3
A1 Saga, Tsuneo
A1 Endo, Keigo
A1 Akiyama, Tetsu
A1 Sakahara, Harumi
A1 Koizumi, Mitsuru
A1 Watanabe, Yuji
A1 Nakai, Toshiharu
A1 Hosono, Makoto
A1 Yamamoto, Tadashi
A1 Toyoshima, Kumao
A1 Konishi, Junji
YR 1991
UL http://cancerres.aacrjournals.org/content/51/3/990.abstract
AB Class-switched monoclonal antibody SV2-61r recognizes the extracellular domain of c-erbB-2 protooncogene products separate from the epidermal growth factor receptor. We studied the potential of SV2-61r for evaluating the amplification of c-erbB-2 protooncogene on cancer cells, which has been reported to have prognostic value in adenocarcinoma patients. Radiolabeled SV2-61r specifically bound to various adenocarcinoma cells in addition to c-erbB-2-transfected NIH-3T3 cells (A4) with the affinity constant of 4.4 × 108 m-1. SV2-61r injected i.v. localized well to A4 cells xenografted in nude mice. Tumor uptake and localization index of radioiodinated SV2-61r were lower than those of 111In-labeled SV2-61r, probably due to the internalization and dehalogenation of formed antibody-antigen complexes. Biodistribution and specificity of targeting were assessed by comparison among three cells, A4, lung cancer SBC-3 (c-erbB-2 weakly positive) and B-lymphoblastoid Manca cells (c-erbB-2 negative). Tumor:blood ratios, obtained 48 h after injection, were 5.63, 1.45, and 0.68, respectively, indicating the potential of 111In-labeled SV2-61r for evaluating the amplification of c-erbB-2 protooncogene on cancer cells. Because of its close relationship with carcinogenesis and the uniform expression, c-erbB-2 protooncogene products seem to be the optimal target of imaging and therapy of adenocarcinoma patients. ©1991 American Association for Cancer Research.